Latest Patents News

INOVIQ Limited clarifies recent share price movements, confirming no undisclosed material information while highlighting an imminent ASCO presentation and provisional patent application tied to its EXO-OC ovarian cancer test.

Atomo Diagnostics has landed a significant $450,000 order to supply HIV self-tests for a federally funded Australian program aimed at increasing at-home testing among high-risk groups.

Ionic Rare Earths, through its Viridion joint venture, has delivered the first recycled rare earth oxides to Brazil’s CIT SENAI ITR, marking a key step toward a domestic magnet supply chain in South America.

Recce Pharmaceuticals has secured a significant patent acceptance in China for its RECCE® anti-infectives, broadening its intellectual property footprint in the world’s second-largest pharmaceutical market.

Ionic Rare Earths has signed a pivotal MOU with EMR to develop a circular supply chain for rare earth magnets, supporting its Belfast recycling plant and the UK’s net-zero ambitions.

Way2VAT unveils a bold growth strategy leveraging patented AI technology to dominate the expanding digital tax processing market, targeting rapid profitability in 2025. The company’s unified SaaS platform integrates VAT reclaim, real-time invoice validation, compliance services, and e-invoicing across 40+ countries.

Way2VAT has secured a significant three-year contract with global real estate giant JLL, deploying its AI-driven VAT recovery and compliance platform across 25 entities worldwide. This deal positions Way2VAT as a key player in automated VAT solutions for multinational corporations.

Proteomics International has validated its PromarkerEndo blood test as a highly accurate, non-invasive diagnostic tool for endometriosis, with commercial launch planned in Australia for Q3 2025. The test promises to reduce the average seven-year diagnostic delay by providing a simple risk score applicable across all disease stages.

Osteopore Limited has drawn down an additional A$500,000 from the first tranche of its redeemable convertible notes, bringing total subscriptions close to the A$5 million tranche limit. The funds will support ongoing operations and future growth initiatives.

Argenica Therapeutics has expanded its intellectual property with a new US patent targeting surgically induced strokes, enhancing the commercial potential of its lead drug candidate ARG-007.

AFT Pharmaceuticals reported a 6% revenue increase to NZ$208 million in FY25, driven by strong ANZ growth and expanding international presence. The company targets NZ$300 million revenue by FY27 amid ongoing R&D and new product launches.

Ardea Resources has received a $1.2 million R&D tax incentive rebate from the Australian Government, reinforcing its innovative work at the Kalgoorlie Nickel Project and strengthening its financial position.